Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls

Ilir Agalliu, Roberto A. Ortega, Marta San Luciano, Anat Mirelman, Claustre Pont-Sunyer, Kathrin Brockmann, Dolores Vilas, Eduardo Tolosa, Daniela Berg, Bjørg Warø, Amanda Glickman, Deborah Raymond, Rivka Inzelberg, Javier Ruiz-Martinez, Elisabet Mondragon, Eitan Friedman, Sharon Hassin-Baer, Roy N. Alcalay, Helen Mejia-Santana, Jan AaslyTatiana Foroud, Karen Marder, Nir Giladi, Susan Bressman, Rachel Saunders-Pullman

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Background: Increased cancer risk has been reported in Parkinson's disease (PD) patients carrying the leucine rich repeat kinase 2 (LRRK2) G2019S mutation (LRRK2-PD) in comparison with idiopathic PD (IPD). It is unclear whether the elevated risk would be maintained when compared with unaffected controls. Methods: Cancer outcomes were compared among 257 LRRK2-PD patients, 712 IPD patients, and 218 controls recruited from 7 LRRK2 consortium centers using mixed-effects logistic regression. Data were then pooled with a previous study to examine cancer risk between 401 LRRK2-PD and 1946 IPD patients. Results: Although cancer prevalence was similar among LRRK2-PD patients (32.3%), IPD patients (27.5%), and controls (27.5%; P = 0.33), LRRK2-PD had increased risks of leukemia (odds ratio [OR] = 4.55; 95% confidence interval [CI], 1.46–10.61) and skin cancer (OR = 1.61; 95% CI, 1.09–2.37). In the pooled analysis, LRRK2-PD patients had also elevated risks of leukemia (OR = 9.84; 95% CI, 2.15–44.94) and colon cancer (OR = 2.34; 95% CI, 1.15–4.74) when compared with IPD patients. Conclusions: The increased risks of leukemia as well as skin and colon cancers among LRRK2-PD patients suggest that LRRK2 mutations heighten risks of certain cancers.

Original languageEnglish (US)
Pages (from-to)1392-1398
Number of pages7
JournalMovement Disorders
Volume34
Issue number9
DOIs
StatePublished - Sep 1 2019

Keywords

  • G2019S mutation
  • LRRK2 gene
  • Parkinson's disease
  • colon cancer
  • leukemia
  • pooled analysis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls'. Together they form a unique fingerprint.

Cite this